Definition of remission and relapse in polymyalgia rheumatica: data from a literature search compared with a Delphi-based expert consensus. by Dejaco, Christian et al.
Dejaco, C; Duftner, C; Cimmino, MA; Dasgupta, B; Salvarani, C;
Crowson, CS; Maradit-Kremers, H; Hutchings, A; Matteson, EL;
Schirmer, M (2011) Definition of remission and relapse in polymyalgia
rheumatica: data from a literature search compared with a Delphi-
based expert consensus. Annals of the rheumatic diseases, 70 (3).
pp. 447-453. ISSN 0003-4967 DOI: 10.1136/ard.2010.133850
Downloaded from: http://researchonline.lshtm.ac.uk/1106/
DOI: 10.1136/ard.2010.133850
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: http://creativecommons.org/licenses/by-nc-nd/2.5/
Extended report
Ann Rheum Dis 2011;70:447–453. doi:10.1136/ard.2010.133850 447
Accepted 2 October 2010
Published Online First 
19 November 2010
 ABSTRACT 
 Objective  To compare current defi nitions of remission 
and relapse in polymyalgia rheumatica (PMR) with items 
resulting from a Delphi-based expert consensus. 
 Methods  Relevant studies including defi nitions of PMR 
remission and relapse were identifi ed by literature search 
in PubMed. The questionnaire used for the Delphi survey 
included clinical (n=33), laboratory (n=54) and imaging 
(n=7) parameters retrieved from a literature search. 
Each item was assessed for importance and availability/
practicability, and limits were considered for metric 
parameters. Consensus was defi ned by an agreement 
rate of ≥80%. 
 Results  Out of 6031 articles screened, defi nitions of 
PMR remission and relapse were available in 18 and 
34 studies, respectively. Parameters used to defi ne 
remission and/or relapse included history and clinical 
assessment of pain and synovitis, constitutional 
symptoms, morning stiffness (MS), physician’s global 
assessment, headache, erythrocyte sedimentation rate 
(ESR), C-reactive protein (CRP), blood count, fi brinogen 
and/or corticosteroid therapy. In the Delphi exercise a 
consensus was obtained on the following parameters 
deemed essential for defi nitions of remission and relapse: 
patient’s pain assessment, MS, ESR, CRP, shoulder and 
hip pain on clinical examination, limitation of upper limb 
elevation, and assessment of corticosteroid dose required 
to control symptoms. 
 Conclusions  Assessment of patient’s pain, MS, ESR, 
CRP, shoulder pain/limitation on clinical examination and 
corticosteroid dose are considered to be important in 
current available defi nitions of PMR remission and relapse 
and the present expert consensus. The high relevance of 
clinical assessment of hips was unique to this study and 
may improve specifi city and sensitivity of defi nitions for 
remission and relapse in PMR. 
 INTRODUCTION 
 Polymyalgia rheumatica (PMR) is a common dis-
ease in older people conventionally treated with 
long-term oral corticosteroids.  1  –  6  
 As corticosteroid treatment leads to rapid 
improvement in symptoms and returns patients to 
pre-morbid functional status, interventional studies 
in PMR usually focus on parameters such as ‘com-
plete remission’ or ‘time in remission to relapse’, 
rather than on partial response criteria used in other 
immune-mediated diseases.  7  –  10  However, there is 
still considerable uncertainty related to deﬁ nitions 
of ‘remission’ and ‘relapse’ in PMR, with disparate 
use of criteria used to deﬁ ne these disease states in 
PMR treatment studies to date. 
 New deﬁ nitions of remission and relapse have 
been proposed by Leeb  et al  11  and Binard  et al ,  12  
respectively. Both deﬁ nitions were based on the 
PMR activity score (PMR-AS), which was devel-
oped using predeﬁ ned parameters and was not 
subject to a consensus ﬁ nding process including 
a systematic literature review. 13  14 The validity of 
the PMR-AS has been supported in a number of 
 studies.  11    12    15    16  
 This paper presents the results from a Delphi-
based consensus survey involving rheumatologists 
(RMs) and general practitioners (GPs) identifying 
candidate items for new deﬁ nitions of remission 
and relapse. We compared these parameters with 
currently available remission and relapse deﬁ ni-
tions retrieved from a systematic literature review. 
 METHODS 
 Literature search 
 A literature search was conducted in PubMed, 
Medline (from January 1966 to November 2003, 
updated June 2009), using the items ‘Polymyalgia 
rheumatica’, ‘PMR’, ‘Giant cell arteritis’, 
‘Polymyalgia rheumatica AND Remission’ and 
‘Polymyalgia rheumatica AND Relapse’ as key-
words. Only studies written in English were 
included. All studies were screened for deﬁ nitions 
of remission and/or relapse of PMR and parameters 
used to deﬁ ne these conditions in PMR. 
 Delphi exercise 
 We used a two-step Delphi process. Firstly, we 
generated a questionnaire with candidate items 
for deﬁ nitions of remission and relapse of PMR as 
retrieved in a literature search. The ﬁ nal question-
naire included 94 items categorised into ‘history’ 
(n=19), ‘physical examination’ (n=14), ‘laboratory 
ﬁ ndings’ (n=54) and ‘imaging methods’ (n=7). One 
questionnaire each was used to assess the deﬁ nition 
of remission on treatment medication (reﬂ ecting 
short-term response to corticosteroids), remission 
off medication (longer-term outcome after with-
drawal of corticosteroids) and relapse (when the 
patient is still taking corticosteroids). Availability 
and practicability of all criteria were separately 
assessed. In the ﬁ rst round, experts indicated the 
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Owing to the low response rate from GPs, we restricted our ﬁ nal 
analyses of both questionnaire rounds to results derived from 
RMs. The omission of data from GPs did not signiﬁ cantly alter 
the results of the Delphi exercise. Pooled data for RMs and GPs 
are shown in online supplementary tables 1b, 2b, 3b and 4. 
 Results of the fi rst questionnaire round 
 After the ﬁ rst questionnaire round, 64 out of 94 parameters were 
considered ‘not important’ for the deﬁ nition of remission, and 
65/94 were considered ‘not important’ for deﬁ ning relapse by 
the majority of RMs. The 64 parameters for remission included 
6/19 from the category history, 2/14 from physical examination, 
50/54 from laboratory ﬁ ndings, and 6/7 from imaging methods. 
The 65 parameters considered not important for deﬁ ning relapse 
included 7/19 from history, 2/14 from physical examination, 
50/54 from laboratory ﬁ ndings, and 6/7 from imaging methods. 
 Questionnaires related to remission ‘on medication’ and ‘off 
medication’ showed very high agreement (κ 0.93). Data from 
both questionnaires led to exclusion or consensus on the same 
parameters except for the parameter ‘patient’s assessment of 
pain related to neck, upper arms, shoulders and pelvic girdle by 
a VAS’, which was considered to be essential by 81.8% of RMs 
for ‘remission on medication’ (=consensus), and by 79.2% for 
‘remission off medication’. 
 Availability of items for defi nitions of remission and relapse 
 Of 94 parameters from the literature, 29 were considered as rou-
tinely available/practicable by more than 80% of RMs (10/19 
parameters out of the category history, 12/14 out of clinical 
examination, 7/54 out of laboratory ﬁ ndings, and 0/7 out of 
imaging methods) (see online supplementary tables 1a and 2a 
for detailed results). 
 Eight parameters (all blood tests for cytokines or cytokine 
receptors) were considered to be not available. 
 Results of the second questionnaire round 
 Tables 4 (remission) and  5 (relapse) depict those items for which 
RMs achieved a consensus following the two Delphi rounds. 
The limits for metric parameters were proposed in the ﬁ rst ques-
tionnaire round and rated in the second round. 
 Assessment of symmetric synovitis with peripheral oedema 
as seen in RS 3 PE (remitting seronegative syndrome with pitting 
oedema), peripheral arthritis, patient’s and physician’s global 
assessment, history of transient visual symptoms, fever and 
physician’s pain assessment were important for >50% of RMs in 
deﬁ ning remission and relapse in both questionnaire rounds but 
did not reach consensus level (see online supplementary table 3a 
for detailed results). 
 Comparison of parameters resulting from Delphi exercise with 
previous defi nitions of remission and relapse of PMR 
 Previous deﬁ nitions of remission and relapse not based on 
PMR-AS included the parameters patient’s assessment of pain 
importance (‘essential’, ‘less important’ or ‘not important’) and 
availability/practicability (‘routinely available/practicable’, ‘not 
always available/difﬁ cult to perform’ or ‘not available/practi-
cable’) of diagnostic tools. Availability of diagnostic tools was 
examined in this round only. Experts were encouraged to add 
further candidate criteria to be considered for assessment and 
relevant comments. In addition, experts were asked to suggest 
cut-off points for the proposed quantitative candidate criteria 
items based on data from the literature review. Questionnaires 
were distributed to all experts via mail or e-mail. Experts were 
contacted by telephone and/or reminders were sent to encour-
age participation and return of questionnaires. 
 The questionnaire used in the second round was derived 
from that of the ﬁ rst round using results from the ﬁ rst round. 
Parameters considered ‘not available’ or ‘not important’ by ≥50% 
or ‘essential’ by <20% of experts were excluded. Items regarded 
as essential by ≥80% of experts for the deﬁ nition of remission 
and/or relapse were accepted as consensus items and not fur-
ther assessed. First-round results of the remaining parameters 
were illustrated to the experts by pie diagrams. Then, experts 
were asked to re-evaluate the parameters either as ‘important’ 
or ‘not important’ to the deﬁ nition of remission and/or relapse 
of PMR. In addition, experts were encouraged to choose a limit 
for quantitative items among those proposed in the ﬁ rst round. 
All written comments were attached anonymously. 
 As ﬁ rst-round analysis of questionnaires for remission ‘on 
medication’ and ‘off medication’ showed almost perfect agree-
ment, no separate assessment for remission ‘on medication’ and 
‘off medication’ was performed in the second round. Only the 
parameter ‘patient’s assessment of pain related to neck, upper 
arms, shoulders and pelvic girdle by a visual analogue scale 
(VAS)’ revealing some disagreement was reassessed. 
 Experts 
 We invited 25 RMs from Europe (Italy (n=6), Sweden (n=1), UK 
(n=2), France (n=1), Austria (n=3), Spain (n=2), Germany (n=3)), 
Israel (n=1) and the USA (n=6) experienced in treatment and 
research of PMR to participate. Most of them are members of 
the International Work Group for PMR and GCA. 17 RMs were 
asked to propose one GP experienced in treating patients with 
PMR and willing to participate in the study. 
 Statistical analysis 
 Statistical analyses were performed using SPSS, V.11.0. Responses 
were analysed by descriptive statistics as appropriate. Invalid or 
missing data were excluded. 
 RESULTS 
 Literature research 
 Of 6031 articles screened, 1851 were excluded because they 
were written in a language other than English, and 2500 reports 
were editorials, comments, or letters without original data. Of 
the 1680 remaining papers, we identiﬁ ed 18 and 34 that con-
tained deﬁ nitions of PMR remission and relapse, respectively: 
one paper each with a deﬁ nition of PMR remission and relapse 
based on PMR-AS ( table 1 ) and an additional 17 and 33 papers 
containing remission and relapse criteria not based on PMR-AS, 
respectively ( tables 2 and  3 ). 
 Delphi exercise 
 Responses by invited physicians to the ﬁ rst round of question-
naires were 34/50 (25 RMs (100%) and nine GPs (36%)) and to 
the second round 22/34 (19 RMs (76%) and three GPs (12%)). 
 Table 1  Defi nitions of remission and relapse based on the polymyalgia 
rheumatica activity score (PMR-AS) by Leeb and Bird  14  
 PMR-AS=CRP (mg/dl)+patient’s pain assessment (VAS 0–10)*+physician’s 
global assessment (VAS 0–10)†+(morning stiffness (min)×0.1) + EUL (0–3)‡ 
Remission  11  0–1.5
Relapse  12  >9.35 or a ΔPMR-AS score >6.6
 *0=no pain; 10=unbearable pain. 
 †0=no disease activity; 10= highest possible activity. 
 ‡0=above shoulder girdle; 1=up to shoulder girdle; 2=below shoulder girdle; 3=none. 
 CRP, C-reactive protein; EUL, ability to elevate the upper limbs; VAS, visual analogue 
scale. 
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studies with deﬁ nitions of remission and relapse, respectively, 
and was not included in the PMR-AS. In addition, we observed 
a high relevance (>50% agreement) of peripheral manifestations 
and fever compared with previous literature. Hips are involved 
in 50–70% of patients with PMR, and peripheral or constitu-
tional symptoms occur in 30–50%. 18 Assessment of these clini-
cal features with incorporation into deﬁ nitions of remission and 
relapse may lead to higher speciﬁ city and sensitivity of these 
deﬁ nitions and possibly allow improved classiﬁ cation of those 
10–30% of patients who lack shoulder symptoms.  18  
 Clear improvement in, or ﬂ are of, PMR using clinical symp-
toms such as pain or MS was considered to be important by 
experts in the present survey. These parameters are included 
in the PMR-AS, and most proposed remission and/or relapse 
deﬁ nitions in the current literature. However, this international 
PMR/GCA study group recently questioned the value of MS, as 
patients and clinicians may not reliably distinguish between pain 
and stiffness.  17  A major concern is that pain-related items may 
lack speciﬁ city given the high prevalence of osteoarthritis and 
degenerative pain in older people.  19  The occurrence of unilateral 
versus bilateral pain may be useful in this regard; however, a 
prospective study is needed to clarify the true value of pain and 
stiffness in deﬁ ning remission and relapse in PMR. 
 The biometric limits for clinical items (eg, duration of MS) 
chosen by experts in the present survey were comparable to 
those available from a literature search and the PMR-AS. In the 
present Delphi survey and previous deﬁ nitions of remission 
and relapse, cut-off values were preferred to relative changes 
in the parameters during follow-up. A relevant consideration 
in this regard is that all such measures should be zero for a 
PMR patient in remission. However, many older patients with 
arthritic/rheumatic conditions rarely consider themselves to be 
completely free from pain and stiffness.  20  Therefore, several 
(29.4% and 21.2%, respectively), MS (23.5% and 21.2%, respec-
tively), ESR (70.6% and 60.6%, respectively), CRP (29.4% and 
30.3%, respectively) and shoulder pain/limitation on clinical 
examination (11.8% and 0%, respectively); and these param-
eters also reached consensus level in the Delphi exercise and 
are included in the PMR-AS (ESR may be used instead of CRP 
according to the original work by Leeb  et al  13    14  ). Physician’s 
global assessment is part of the PMR-AS, but did not achieve 
consensus level in the Delphi study with 57.9% and 56.2% 
agreement for remission and relapse, respectively. Assessment 
of corticosteroid dose (remission)/response to corticosteroids 
(relapse) and hip symptoms judged to be important by >80% 
of experts in the Delphi survey are not part of the PMR-AS and 
were speciﬁ cally included in 17.6% and 11.8% of previous deﬁ -
nitions of remission, respectively, and 60.6% and 12.1% of pre-
vious deﬁ nitions of relapse, respectively, not based on PMR-AS. 
Peripheral synovitis, patient’s global assessment, history of tran-
sient visual symptoms, history of fever, and physician’s pain 
assessment were all important for the majority of RMs in the 
Delphi exercise, but are considered by <6% of previous remis-
sion and relapse deﬁ nitions including the PMR-AS. 
 DISCUSSION 
 This international Delphi survey among RM experts corrob-
orated some previously proposed items for the deﬁ nition of 
PMR remission and relapse including patient’s assessment of 
pain, MS, ESR, CRP, shoulder pain/limitation on clinical exami-
nation, and corticosteroid dose required to control symptoms. 
Many other items, such as determination of haemoglobin 
and ﬁ brinogen, were considered to have little value for this 
purpose. 
 The consensus on hip involvement was unexpected, as this 
parameter was only considered in 2/17 and 4/33 previous 
 Table 2  Defi nitions of remission of polymyalgia rheumatica from the published literature 
 Reference  History  Clinical examination 
 Laboratory 
 Therapy 
 ESR 
(mm/1st h)  CRP (mg/dl)  Blood count 
 Fibrinogen 
(μmol/l) 
Behn  et al  30  ACS <30 − − − −
Cantini  et al  27  ACS <40 <0.5 * − − −
Catanoso  et al  9  Absence of systemic symptoms 
(fever, malaise, anorexia, weight 
loss), MS, girdles and neck pain 
and peripheral synovitis
− <40 <0.5 * − − −
Chuang  et al  41  ACS Normal laboratory fi ndings –
Dasgupta  et al  42  ≥50% pain reduction (VAS) MS 
<30 min
− <20 – Hb >12 g/dl − −
Delecoeuillerie  et al  43  ACS − − − – −
Feinberg  et al  44   Absence of pain on 
examination
NV − – − −
Ferraccioli  et al  45  Absence of myalgias − NV NV – − −
Hutchings  et al  46  ≥50% improvement in shoulder 
and pelvic girdle pain on a VAS, 
MS ≤30 min
− ≤30 ≤1.0 – − −
Kremers  et al  31    34    35  ACS NV − − − CS ≤5 mg/day
Krogsgaard  et al  47  No muscular pain, no MS No muscular tenderness NV − – NV Lowest CS possible
Martinez-Taboada  et al  48  ACS NV − − − −
Mertens  et al  49  ACS − − − − −
Proven  et al  36  ACS      
Salvarani  et al  26  ACS ≤30 ≤0.5 * − − −
Salvarani  et al  8  ACS NV − − − −
Van der Veen  et al 50       Discontinuation of prednisone 
and trial medication
 * The upper limit of normal is 0.5 mg/dl; for the other studies, no upper limit of normal CRP levels was reported. 
 −, parameter not mentioned in the defi nition. 
 ACS, absence of clinical symptoms (not further specifi ed); CRP, C-reactive protein; CS, corticosteroid dose; ESR, erythrocyte sedimentation rate; Hb, haemoglobin; MS, morning 
stiffness; NV, normal values; VAS, measured on a visual analogue scale ranging from 0 (best) to 10 (worst) cm. 
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 In this Delphi exercise, both ESR and CRP were assumed to 
be routinely available and to be the most promising laboratory 
items for deﬁ ning both remission and relapse. While CRP is a 
component of the PMR-AS, other published studies have pref-
erentially used a normal ESR as a component of their remis-
sion deﬁ nition. Persistently raised CRP has been suggested to 
correlate better with inﬂ ammation in PMR than ESR and may 
thus be better suited for use in deﬁ nitions of remission and 
relapse.  26  An important limitation of CRP and ESR is that these 
may be normal (not increased) in up to 20% of patients with 
PMR at the time of diagnosis.  18  Indeed, normal ESR or CRP 
values have been observed in up to 27% and 14% of relapses, 
respectively, despite the increase in these parameters at the 
time of diagnosis.  10    27  –  29  Thus a ﬂ are of PMR symptoms may 
occur in the absence of abnormal inﬂ ammatory parameters, 
although degenerative pain with stiffness may also mimic a 
ﬂ are of the disease. 
PMR studies deﬁ ne remission pragmatically as absence of 
relapse or as duration of relapse-free survival, accepting higher 
(non-zero) biometric limits for patients in remission.  21  –  25  This 
strategy for deﬁ ning remission has the advantage of a high sen-
sitivity, classifying all patients with PMR as either in remis-
sion or relapse. In contrast, developing separate remission and 
relapse criteria results in a high speciﬁ city of classiﬁ cation, 
but suggests an additional (yet undeﬁ ned) disease state that 
is neither remission nor relapse. Sensitivity and speciﬁ city of 
such deﬁ nitions may differ, if relevant parameters are used as 
a qualitative set of criteria or a composite score, such as the 
PMR-AS. In rheumatoid arthritis and other rheumatic diseases, 
composite scores are usually preferred, whereas most treat-
ment studies in PMR to date have used qualitative sets of cri-
teria. The question of which approach is more useful for daily 
clinical practice and outcome studies remains to be addressed 
by future studies. 
 Table 3  Defi nitions for relapse of polymyalgia rheumatica from the published literature 
 Reference  Elevation of ESR *  (mm/1st h)  Elevation of CRP (mg/dl)  Flare of PMR clinical features *  Response to corticosteroids *
Amoli  et al  51  − − Yes Yes
Ayoub  et al  38  − − Yes Yes
Bahlas  et al  33  − − Yes Yes
Bengtsson and Malmvall 28 − − Yes −
Behn  et al  30  NN − Yes −
Blockmans  et al  21  >40 (NN) >3.0 (NN) † MS, proximal girdle pain −
Cantini  et al  27  >30 (NN) − Yes Yes
Caporali  et al  10  >30 ‡ >0.5 Aching and stiffness at shoulder, 
hip girdle, or both
−
Catanoso  et al  9  ≥40 ‡ ≥0.5 † Typical proximal musculoskeletal 
symptoms, MS ≥1 h
−
Ceccato  et al  52  NN − Yes Yes
Chuang  et al  41  NN − Yes Yes
Cimmino  et al  53    54  >30 ‡ >0.5 Aching and stiffness at shoulder 
and/or hip girdle
−
Cutolo  et al  55  >30 (NN) − Yes −
Delecoeuillerie  et al  43  − − Yes Yes
Ferraccioli  et al  45  >100% more than previous 
assessment ‡ 
>100% more than previous 
assessment
Return of myalgia −
González-Gay  et al  32  NN − Yes Yes
González-Gay  et al  56  − − Yes Yes
Hachulla  et al  22  >30 ‡ >1.2¶ Fever, proximal aching and MS, myalgia, 
weakness, weight loss, headache (NN)§
Yes (or to dapsone)
Hutchings  et al  46  − − Yes Yes or maintenance of the steroid 
dose beyond a scheduled reduction
Kremers  et al  31  − − Yes Yes (and requiring a dose increment 
≥5 mg/day)
Kremers  et al  34  − − Yes Yes
Kyle and Hazleman  57  − − Pain and stiffness in the shoulder or 
hip girdle
−
Lundberg and Hedfors  58  − − Yes Yes
Mertens  et al  49  − − Yes Yes
Narváez  et al  23  Yes − Yes Yes
Pego-Reigosa  et al 24 − − Yes −
Proven  et al  36  Yes − Yes −
Pulsatelli  et al  59  >30 >0.5 † Yes Yes
Salvarani  et al  25    60  >30 (NN) − Yes −
Salvarani  et al  26  >30 ‡ >0.5 † Yes Yes
Salvarani  et al  8  >30 ‡ >0.5 † Aching and stiffness at shoulder, 
hip girdle or both
Yes
van der Veen  et al  50  >100% more than previous 
assessment ‡ 
>100% more than previous 
assessment
Yes −
von Knorring  29  NN − Yes Yes
 −, parameter not mentioned in the defi nition. 
 *Not further specifi ed unless otherwise stated. 
 ‡ Incremental change in either ESR or CRP for the defi nition of relapse. 
 §No other intercurrent infl ammatory syndrome. 
 CRP, C-reactive protein; the upper limit of normal is  † 0.5 mg/dl and ¶1.2 mg/dl (for the other studies, no upper limit of normal CRP levels was reported); ESR, erythrocyte sedimentation 
rate; MS, morning stiffness; NN, not necessarily. 
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dose may be important to the deﬁ nition of remission. A related 
consideration is that physicians and patients may be unwilling 
to accept the status of ‘remission’ if achieved at the expense 
of serious impairment of the patient’s general well-being due 
to side effects of unacceptably high corticosteroid doses.  11  
Maintaining a treatment-free complete clinical response after 
stopping treatment remains the clinical goal, which is not 
always achievable in PMR.  11    33  
 In the present survey, >80% of experts were of the opinion 
that corticosteroid doses should be included in any deﬁ nition of 
remission in PMR. While agreeing that the corticosteroid dose 
‘should be as low as possible’, a speciﬁ ed dose limit was not 
agreed upon. A prospective study would be needed to clarify 
whether the assessment of corticosteroid doses improves the 
speciﬁ city of a deﬁ nition of remission. 
 A relapse of PMR can be deﬁ ned even with normal CRP and/
or ESR using the PMR-AS and deﬁ nitions from 22 of the 33 other 
studies from the literature search. Notably, the PMR-EULAR 
response criteria that provide the basis for the PMR-AS were 
developed in a cohort of PMR patients who all had raised ESR and 
CRP values at the time of diagnosis.  13  In the present survey, the 
possibility of relapse in the absence of abnormally increased ESR 
and/or CRP was not addressed and requires future clariﬁ cation. 
 The other laboratory parameters evaluated, including blood 
count, markers of vascular damage/activation, hormones and 
cytokines/receptors, were considered less important in evaluat-
ing relapse and remission at this point in time. 
 Corticosteroids are the mainstay of treatment for PMR, 
although the optimal initial dose and tapering regimen are 
matters of ongoing debate.  1    30  –  32  Assessment of corticosteroid 
 Table 4  Parameters considered as ‘important’ for defi ning remission of polymyalgia rheumatica by at least 
80% of rheumatologists (RMs) 
 Parameter  Limits  Agreement (%) 
Morning stiffness * <15 min
<30 min
94.7
 5.3
Erythrocyte sedimentation rate *  < 20 mm/1st h
<30 mm/1st h
<40 mm/1st h
57.9
31.6
10.5
C-reactive protein *,†  < 0.5 mg/dl
<0.8 mg/dl
<1.0 mg/dl
68.4
10.5
21.2
Patient’s assessment of pain related to neck, upper arms, 
shoulders and pelvic girdle (VAS)
 < 10 mm
<20 mm
<25 mm
58.8
35.3
 5.9
Corticosteroid dose required to control symptoms * Limit not specifi ed‡
Shoulder-pain worsened by passive and active mobilisation Qualitative item
Limitation of upper limb elevation Qualitative item
Clinical signs of coxofemoral synovitis § Qualitative item
 The corresponding proposals for limits of metric parameters and the agreement to these limits are given. 
 *Consensus on this parameter was already obtained in the fi rst Delphi round. 
 †Upper limit of a normal C-reactive protein value is 0.5 mg/dl. 
 ‡ A certain corticosteroid dose limit for remission on treatment medication (ie, when a patient is still on corticosteroids) was not 
specifi ed by RMs in the Delphi survey. Corticosteroid dose of zero defi nes the case of remission off medication (ie, when the patient 
stopped taking corticosteroids). 
 § Coxofemoral synovitis is suggested if the patient complains about pain in the groin worsened by passive and active movements on 
clinical examination. 
 VAS, visual analogue scale with 0=no pain, 10=unbearable pain on a 10 cm scale. 
 Table 5  Parameters considered as ‘important’ to defi ne relapse of polymyalgia rheumatica by at least 80% 
of rheumatologists (RMs) 
 Parameter  Limits  Agreement (%) 
Morning stiffness* >30 min
+20%
94.7
 5.3
Erythrocyte sedimentation rate *  > 40 mm/1st h
>20 mm/1st h
≥2 × previous
57.9
36.8
 5.3
C-reactive protein *,†  > 1.0 mg/dl
>0.5 mg/dl
>2.0 mg/dl
≥2 × previous
52.6
21.1
15.9
10.5
Patient’s assessment of pain related to neck, upper arms, shoulders and 
pelvic girdle (VAS) * 
 > 20 mm
>50 mm
93.8
 6.2
Corticosteroid dose required to control symptoms * Any dose ↑
+2.5 mg/day
≥10 mg/day
62.4
31.2
 6.2
Shoulder pain worsened by passive and active mobilisation Qualitative item
Limitation of upper limb elevation Qualitative item
Clinical sign of coxofemoral synovitis ‡ Qualitative item
 The corresponding proposals for a limit of metric parameters and the agreement rate to these limits are given. 
 *Consensus on this parameter was already obtained in the fi rst Delphi round. 
 †Upper limit of a normal C-reactive protein value is 0.5 mg/dl. 
 ‡Coxofemoral synovitis is suggested if the patient complains about pain in the groin worsened by passive and active movements on 
clinical examination. 
 VAS, visual analogue scale with 0=no pain, 10=unbearable pain on a 10 cm scale. 
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 The majority of experts thought that the need for any incre-
ment in corticosteroid dose necessary to control PMR symp-
toms should be included in the criteria for deﬁ ning relapse. This 
result is in accordance with 20 studies from our literature search, 
which considered a ﬂ are of PMR symptoms to be a relapse if 
symptoms respond to an increased dose of corticosteroid. 
 To address possible differences related to useful parameters 
for assessing short-term (ie, remission when the patient is tak-
ing corticosteroids) and long-term (ie, remission after treatment 
withdrawal) outcomes in PMR, we used different question-
naires to deﬁ ne remission ‘on medication’ and ‘off medication’. 
The ratings of the two questionnaires showed almost perfect 
agreement, indicating that the same clinical parameters may be 
useful for deﬁ ning both states of remission. However, we did 
not address the role of time with respect to remission, as has 
been reported previously.  30    31    34  –  37  The time in remission after 
withdrawal of treatment is of particular interest in distinguish-
ing patients in ‘permanent’ remission or at low risk of relapse 
from those at high risk of relapse.  28    38  This issue remains to be 
clariﬁ ed. 
 We invited 50 experts to participate in this Delphi exer-
cise, recognising that no optimal number of experts for such 
a study exists. The reliability of results may decline rapidly 
with fewer than six panel members, whereas improvements 
in reliability are relatively small in groups larger than 15.  39    40  
There is also no deﬁ nition of an ‘expert’ status for a Delphi 
study, but, as PMR is diagnosed by RMs and GPs, we sought 
to consider opinions of both groups of physicians. A survey 
among French GPs revealed that only 36% of GPs routinely 
refer PMR patients to a RM for diagnosis of the disease and 
that only 20% of these GPs take advice from RMs for rou-
tine follow-up of PMR patients.  15  Therefore we asked partici-
pating RMs to recommend one GP each in order to involve 
an international group of GPs with adequate experience in 
rheumatology. Only nine and three GPs responded to the ﬁ rst 
and second questionnaire rounds, respectively, despite recur-
rent telephone contacts and/or written reminders. The low 
response rate for GPs limits the validity of their responses, 
and therefore we restricted our ﬁ nal analysis to data derived 
from RMs. The omission of data from GPs, however, did not 
signiﬁ cantly alter the results. 
 The two rounds of questionnaires resulted in a quite lim-
ited number of parameters being accepted by the majority of 
experts. Many others did not achieve the predeﬁ ned level of 
consensus. It is possible that another round addressing at least 
some of these items further may have resulted in them being 
classiﬁ ed as consensus items or as not important. Further rounds 
of questionnaires were not pursued, in part because of concern 
that respondent fatigue might seriously erode the value of the 
exercise. 
 The items that emerged from this Delphi-based expert consen-
sus as important for deﬁ ning relapse and remission in patients 
with PMR were patient’s assessment of pain related to neck, 
upper arms, shoulders and pelvic girdle, MS, ESR, CRP, shoulder 
pain/limitation on clinical examination, and corticosteroid dose. 
Clinical assessment of the hips turned out to be important in 
this survey and may further improve speciﬁ city and sensitivity 
of deﬁ ning remission and relapse in PMR. The operating charac-
teristics and value of the remission and relapse items derived in 
this exercise will require prospective evaluation. 
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